Abstract
INTRODUCTION
The rising burden of dementia in the Global South is compounded by a substantial diagnostic gap limiting access to biomarker-based diagnosis. We evaluated the diagnostic performance of non-invasive blood-based biomarkers and their ratios across the cognitive continuum in a South Asian cohort to address a lack of evidence beyond Western populations.
METHODS
This study included participants from a Cognitive Disorders Clinic (n = 315), comprising individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), frontotemporal dementia (FTD), and cognitively unimpaired (CU) controls. All participants underwent standardized cognitive assessment and structural brain imaging. Serum phosphorylated tau (p-tau217), p-tau181, and neurofilament light (NfL) were quantified using a Simoa HD-X analyzer. Diagnostic performance of biomarkers and their ratios were assessed, and a novel multi-threshold approach was applied to facilitate their clinical interpretation in routine practice.
RESULTS
Serum p-tau217 and NfL levels were significantly higher in the cognitively impaired group compared to CU, whereas p-tau181 showed no significant difference. Across the diagnostic groups, p-tau217 was highest in AD (F = 12.61, p < 0.001), and NfL in FTD (F = 20.84, p < 0.001). NfL best discriminated FTD versus CU, whereas p-tau217 showed optimal discrimination for AD (area under the curve [AUC] = 0.85). The NfL/p-tau217 ratio improved discrimination between AD and FTD (AUC = 0.78). The multi-threshold approach demonstrated superior diagnostic performance compared to single cut-off.
DISCUSSION
Serum p-tau217, NfL, and NfL/p-tau217 ratio showed robust diagnostic accuracy in this diverse South Asian cohort. The multi-threshold approach improved the clinical interpretability, supporting the integration of blood-based biomarkers (BBMs) in clinical practice, enabling timely diagnosis and accurate determination of therapeutic eligibility.


If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: | November 17, 2026
Neuro-Dementia